PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfolliclestem cells, but minoxidil and finasteride are still the main treatments.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hairfollicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
PP405 is a promising new hair loss treatment that may reactivate dormant hairfollicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.